Business Context and Reporting Period
Company: Pacira BioSciences, Inc. (PCRX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Pacira is a biopharmaceutical company focused on delivering innovative, non-opioid pain therapies. Its commercial portfolio includes EXPAREL (long-acting local analgesic), ZILRETTA (extended-release corticosteroid for osteoarthritis), and iovera (cryoanalgesia device). The company is advancing a pipeline led by PCRX-201, a gene therapy for knee osteoarthritis, following the February 2025 acquisition of GQ Bio Therapeutics GmbH.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $726.4 million | $701.0 million | +4% |
| Net Product Sales | $722.9 million | $697.2 million | +4% |
| Gross Margin | 79% | 76% | +3 percentage points |
| Net Income (Loss) | $7.0 million | $(99.6) million | Turnaround to Profit |
| Operating Cash Flow | $152.0 million | $189.4 million | -$37.4 million |
| Total Debt (Gross) | $378.5 million | $585.3 million | -$206.8 million |
| Cash & Investments | $238.4 million | $484.6 million | -$246.2 million |
Note: 2024 Net Loss included a $163.2 million goodwill impairment charge. 2025 Net Income benefited from a $23.1 million legal judgment recovery.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 4% year-over-year. EXPAREL sales grew 5% to $575.1 million (driven by a 6% volume increase), while ZILRETTA sales declined 1% to $116.6 million due to lower kit volume. iovera sales increased 6% to $24.2 million.
- Profitability Improvement: The company returned to profitability with $7.0 million in net income, compared to a $99.6 million loss in 2024. This shift was driven by the absence of the 2024 goodwill impairment, a $23.1 million legal judgment recovery from the Research Development Foundation (RDF), and improved gross margins.
- Debt Reduction: Total consolidated gross indebtedness decreased significantly to $378.5 million. The company repaid the remaining $202.5 million of its 2025 Convertible Senior Notes at maturity in August 2025 and refinanced its Term Loan A facility into a new $300 million Revolving Credit Facility in July 2025.
- Restructuring: In July 2025, the company decommissioned its 45-liter EXPAREL manufacturing suite to improve efficiencies, resulting in a reduction of 71 employees and $3.7 million in restructuring charges.
Guidance, Outlook, and Risks
Management Commentary and Strategy
Management is executing the "5x30" strategic growth plan, aiming to deliver products to over 3 million patients annually by 2030. In 2025, the company reached 2.5 million patients. Key strategic moves include:
- Partnerships: Entered a co-promotion agreement with Johnson & Johnson MedTech for ZILRETTA (July 2025) and a partnership with LG Chem to commercialize EXPAREL in select Asian-Pacific markets (January 2026).
- Pipeline Progress: Completed enrollment for Part A of the Phase 2 ASCEND trial for PCRX-201 (gene therapy for knee OA) and initiated Part B. Received FDA clearance for a new iovera Smart Tip for chronic low back pain.
- Capital Allocation: Authorized a $300 million share repurchase program in April 2025; repurchased $151.4 million of stock during 2025, with $150 million remaining available.
Risks and Contingencies
- Patent Litigation: The company settled patent infringement suits with eVenus ANDA Filers in April 2025, agreeing to a $7.0 million payment and a volume-limited generic entry starting in early 2030. However, new Paragraph IV certifications were received in October 2025 from WhiteOak and Qilu, leading to new litigation filed in November 2025.
- Regulatory & Reimbursement: Success depends on maintaining third-party payer coverage. The NOPAIN Act (effective Jan 1, 2025) mandates Medicare reimbursement for non-opioid products in outpatient settings, which is viewed as a positive tailwind.
- Manufacturing Concentration: Reliance on specific manufacturing sites (San Diego, Swindon UK, Tijuana Mexico) creates supply chain risks.
- Intangible Asset Impairment: Recognized a $25.9 million impairment charge in 2025 related to the ZILRETTA shoulder OA asset due to revised clinical trial timelines.
Investor Verification Checklist
- Patent Expiry & Litigation: Verify the status of the new litigation against WhiteOak and Qilu and the terms of the eVenus settlement regarding generic entry dates (early 2030).
- Debt Covenants: Review the financial covenants in the new Revolving Credit Facility and the 2029 Convertible Senior Notes to ensure compliance with leverage ratios.
- PCRX-201 Milestones: Monitor the interim analysis results of the Phase 2 ASCEND trial for PCRX-201, expected before the end of 2026, as this is a key value driver.
- Share Repurchase Impact: Assess the impact of the remaining $150 million repurchase authorization on liquidity and future capital deployment.
- Reimbursement Trends: Track the actual uptake of the NOPAIN Act reimbursement codes (J0666 for EXPAREL, C9809 for iovera) in hospital outpatient departments.